Nami Surgical
Nami Surgical develops miniaturised ultrasonic surgical scalpels compatible with wristed robotic-assisted surgery platforms, serving surgical robotics OEMs and hospitals. The Glasgow-based University of Glasgow spin-out is pre-commercial, targeting the multi-billion-dollar robotic surgery market with its Nami S™ platform.
- Company typePrivate
- Founded2021
- HeadquartersGlasgow, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Nami Surgical does
Nami Surgical Ltd. is a University of Glasgow spin-out, founded in December 2021, developing miniaturised ultrasonic surgical scalpels for integration into robotic-assisted surgical platforms. The company's core product — the Nami S™ — is the first ultrasonic scalpel compatible with wristed robotic instruments, featuring a diameter of less than 10mm and length of less than 40mm (approximately 90% smaller than incumbent ultrasonic devices) while maintaining tissue-cutting and vessel-sealing performance comparable to gold-standard technology, including the ability to seal blood vessels up to 7mm in diameter. The technical platform rests on a patented miniaturisation approach that preserves the operational vibrational frequency of larger ultrasonic devices, enabling integration with articulated robotic joints; an associated modular smart ultrasonic generator provides millisecond-level energy-delivery control.
The company operates a dual-channel go-to-market targeting both surgical robotics OEMs (via development contracts, licensing, and co-development of next-generation ultrasonic tools) and hospitals or surgical centres performing robotic-assisted procedures (direct sale of ultrasonic scalpels). Pipeline products extend the platform into hand-held ultrasonic scalpels for laparoscopic procedures. Revenue streams are anticipated from hardware sales, technology licensing/royalties, and milestone-based development contracts, though the company is pre-commercial as of January 2026 with pilot programmes running in the United States and globally.
Nami has raised approximately £5.5 million to date across Innovate UK grants, a £3.2M 2024 seed round (£2.5M Eos-led plus £700K Innovate UK grant), and a £1.9M 2026 seed extension. A $10 million Series A was opened in 2025. The leadership team combines the two co-founder PhDs (Nico Fenu, COO; Rebecca Cleary, CTO) with a recently-appointed commercial CEO (Nikki Palfrey, formerly of Summit Medical, BOWA Medical, and Orthosonics International), a Chair with Stryker/Orthofix experience (Albert Nicholl), and high-profile IP advisor Kevin Houser (original Harmonic Scalpel engineer at Ethicon Endo-Surgery/J&J). Headcount is 20–30 with further expansion planned, and the company operates from a new R&D prototyping lab in Hillington, Glasgow.
Nami Surgical firmographics
Firmographics- Name
- Nami Surgical
- Legal name
- Nami Surgical Ltd.
- Website
- https://namisurgical.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Nami Surgical develops miniaturised ultrasonic surgical scalpels compatible with wristed robotic-assisted surgery platforms, serving surgical robotics OEMs and hospitals. The Glasgow-based University of Glasgow spin-out is pre-commercial, targeting the multi-billion-dollar robotic surgery market with its Nami S™ platform.
- Ownership category
- akta.pro rank
Nami Surgical industry classification
Industry- Product category
- Surgical Robotics Instruments
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Surgical Robotics & Computer-Assisted Surgery Platforms (HLAHADAF)
- akta.pro secondary industries
- Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS) (HLAHADAA), Healthcare & Assistive Robotics (HDAAAIAC)
Keywords
Where Nami Surgical is headquartered
LocationHeadquarters
- HQ city
- Glasgow
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
Nami Surgical business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain
Revenue model
- Ultrasonic Surgical Device Sales: Revenue from sale of miniaturized ultrasonic scalpels and surgical instruments designed for robotic-assisted surgery. The first product from the platform (Nami S) targets the robotic surgery market.
- Technology Licensing: Licensing of patented ultrasonic technology to surgical robotics companies for integration into their systems, including smart ultrasonic generators and hand-held ultrasonic scalpels tailored for laparoscopic procedures.
- Development Contracts: Co-development partnerships with leading surgical robotics companies to develop new generations of ultrasonic tools, potentially including upfront payments and milestone-based revenue.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
Nami Surgical product offering
Product offeringCore offering
Nami Surgical develops and manufactures miniaturized ultrasonic surgical scalpels designed for integration into robotic-assisted surgery platforms. The company's flagship product, the Nami S™, is the first ultrasonic scalpel compatible with wristed robotic surgical instruments, featuring a diameter of less than 10 mm and length of less than 40 mm, capable of sealing blood vessels up to 7 mm in diameter. The platform also includes a modular smart ultrasonic driving system for precise energy delivery control and pipeline products including hand-held ultrasonic scalpels for laparoscopic procedures.
Product overview
Nami Surgical has developed a miniaturized ultrasonic scalpel platform designed specifically for robotic-assisted surgery. The core product is the Nami S™, the first ultrasonic scalpel compatible with wristed robotic surgical systems, featuring a diameter under 10 mm and length under 40 mm. The platform includes a modular smart ultrasonic generator for precise energy delivery control. The product portfolio also includes hand-held ultrasonic scalpels for laparoscopic procedures as part of the development pipeline. All products share the foundational ultrasonic technology enabling tissue cutting and cauterization in minimally invasive surgical settings.
Differentiator
Problem solved
Functional benefit
Brands
- Nami S: The company's first product to enter the market - a miniaturised ultrasonic scalpel specifically developed for robotic-assisted surgeries, co-developed with robotic surgeons, and the first ultrasonic scalpel compatible with robotic assisted surgeries.
Products and services
- Nami S™ The first miniaturized ultrasonic scalpel specifically designed for robotic-assisted surgery, with diameter less than 10 mm and length less than 40 mm, capable of sealing blood vessels up to 7 mm in diameter. It is the first ultrasonic scalpel compatible with wristed robotic surgical instruments, enabling integration with articulated, wristed robotic joints for procedures in urology, gynaecology, colorectal, and cardiology.
- Smart Ultrasonic Generator Part of the Nami product pipeline, a fully modular smart electrical driving system for ultrasonic devices that enables precise control of energy delivery at the surgical site with millisecond-level accuracy.
- Hand-held Ultrasonic Scalpels for Laparoscopic Procedures Part of the Nami product pipeline, hand-held ultrasonic scalpels tailored for laparoscopic procedures, expanding the platform beyond robotic surgery applications and leveraging the same miniaturized transducer technology.
Quantifiable outcome
- Vessel sealing times reduced by 265% since April 2024 through in-house testing improvements
- +4 more outcomes
Companies that use Nami Surgical
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
Nami Surgical technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Nami Surgical partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- Kevin HousercoreFormer key member of Ethicon Endo-Surgery team at Johnson & Johnson and Lead Engineer behind the Harmonic Scalpel brand. Author of over 250 U.S. patents joins as IP Champion and Advisor to shape and protect Nami's intellectual property portfolio.
- Lincoln IPminorLocal IP firm working closely with Kevin Houser and Nami Surgical to protect innovation and expand Nami's IP portfolio in ultrasonic surgical technologies.
- University of BernminorCollaborative partner on the £120,000 Innovate UK Switzerland CR&D Grant titled 'AMNIUS: Advancing Tissue Adaptivity with Additively Manufactured Nitinol Ultrasonic Transducers in Robot-Assisted Surgery'.
- Ultrasurge ProgrammecoreNami is a spin-out from Ultrasurge, a 5-year EPSRC programme grant investigating ultrasound in surgery with over £6m in funding. The programme researches ultrasound effect on tissue, miniaturisation of ultrasound transducers, and using external robots to direct ultrasound in surgery.
- Scottish Enterprise - Additive Manufacturing ProgrammeminorNami joined the Scottish Enterprise funded programme 'Additive Manufacturing – Business and Technology' (AM_BATS) at the University of Strathclyde National Manufacturing Institute Scotland (NMIS) to support product development.
Scale indicators11 records
Recent moves8 records
Expansion highlights6 records
Nami Surgical competitors and assessment
Company assessmentDirect peers
- Ethicon (Johnson & Johnson): Ethicon manufactures the Harmonic ultrasonic scalpel, the dominant ultrasonic surgical energy device that Nami is explicitly seeking to miniaturise for robotic surgery. Same product category, same clinical use cases (cutting and vessel sealing), and the same surgeon customer base — the only difference is the robotic-instrument form factor.
Broad incumbents
- Intuitive Surgical: Intuitive's da Vinci platform is the largest installed base of robotic surgical systems globally. Nami's primary commercial pathway is integration into da Vinci and successor platforms, making Intuitive both a potential partner and the most powerful gatekeeper to Nami's end-market.
- Medtronic: Medtronic offers the Hugo robotic-assisted surgery platform and the LigaSure vessel-sealing portfolio, both directly relevant to Nami's value proposition. As a major robotic OEM with in-house energy instrument development, Medtronic is a natural integration partner and a potential competitor.
- Olympus: Olympus manufactures ultrasonic surgical devices (THUNDERBEAT) and a broad minimally-invasive surgical instrument portfolio. It is one of the natural incumbents competing for the same ultrasonic-in-laparoscopic and laparoscopic-procedure use cases Nami targets in its pipeline.
- Stryker: Stryker operates the Mako robotic-assisted surgery platform and has a significant surgical instruments business. Nami's chair Albert Nicholl came from Stryker, and Stryker is the type of broad medtech incumbent that could acquire or partner with Nami to add ultrasonic capability.
- Smith+Nephew: Smith+Nephew is a diversified medtech incumbent with a sports medicine and surgical instruments portfolio that overlaps with Nami's soft-tissue dissection and vessel-sealing use cases. It is the type of established player that could partner with or acquire a miniaturised ultrasonic platform.
Emerging players
- CMR Surgical: CMR Surgical's Versius is a next-generation robotic surgery platform competing head-to-head with da Vinci. Like Nami, CMR is a UK-headquartered, growth-stage medtech company; it is also a likely integration partner seeking differentiated instruments to win against Intuitive.
- Vicarious Surgical: Vicarious Surgical is developing a next-generation robotic surgery system with a unique single-port architecture. It represents the cohort of emerging robotic platforms that need differentiated wristed instruments (including ultrasonic) to compete with incumbents — a potential partner for Nami.
- Moon Surgical: Moon Surgical is a European robotics startup with a bedside-assistant surgical robot. Like Nami, it is an emerging player seeking to carve out differentiation in the robotic surgery stack against Intuitive's installed base.
- Asensus Surgical: Asensus Surgical develops the Senhance robotic-assisted surgery platform and is one of the smaller public players attempting to compete with Intuitive. It shares Nami's challenge of needing differentiated instrumentation to gain share against the da Vinci installed base.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Nami Surgical social profiles
Digital presenceNami Surgical financial estimates
Financial estimateRevenue estimate
Valuation estimate
Nami Surgical leadership team
Management profileNumber of profiles
Profiles9 records
Nami Surgical funding detail
Funding detailFunding overview
Funding rounds3 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Nami Surgical M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Nami Surgical
What does Nami Surgical do?
Nami Surgical develops and manufactures miniaturized ultrasonic surgical scalpels designed for integration into robotic-assisted surgery platforms. The company's flagship product, the Nami S™, is the first ultrasonic scalpel compatible with wristed robotic surgical instruments, featuring a diameter of less than 10 mm and length of less than 40 mm, capable of sealing blood vessels up to 7 mm in diameter. The platform also includes a modular smart ultrasonic driving system for precise energy delivery control and pipeline products including hand-held ultrasonic scalpels for laparoscopic procedures.
Is Nami Surgical a public or private company?
Nami Surgical is a private company. It is classified as venture growth investor backed and is currently operating.
When was Nami Surgical founded?
Nami Surgical was founded in 2021. It employs 11 to 50 people.
Where is Nami Surgical based?
Nami Surgical is headquartered in Glasgow, United Kingdom, in the Europe region.
How does Nami Surgical make money?
Three revenue lines are on record. Ultrasonic Surgical Device Sales are the primary driver. The others are technology Licensing and development Contracts.
Who are Nami Surgical's main competitors?
Ethicon (Johnson & Johnson) is listed as a direct peer. Broad incumbents are Intuitive Surgical, Medtronic, Olympus, Stryker and Smith+Nephew. Emerging players are CMR Surgical, Vicarious Surgical, Moon Surgical and Asensus Surgical.
Does Nami Surgical have an API?
No public API is recorded for Nami Surgical.
What industry is Nami Surgical in?
Nami Surgical's product category is Surgical Robotics Instruments. Its primary akta.pro industry code is HLAHADAF, Surgical Robotics & Computer-Assisted Surgery Platforms, with a secondary code of HLAHADAA, Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS). Its NAICS code is 339113 and its SIC code is 3841.